- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Osteoporosis Prophylaxis: Menostar Now FDA-Approved
The FDA has approved the use ofan estradiol transdermal system(Menostar), from Berlex LaboratoriesInc., to prevent osteoporosis in postmenopausalwomen. The hormoneis impregnated in a dime-sized, once a-week patch that delivers 14 μg/d ofestradiol: this dosage is half that ofother currently available transdermalestrogen patches. No supplementaryprogestin therapy is generally needed.This product can be prescribed for women who are without a uterus.The most common side effects areirritation at the patch site, joint pain,and leukorrhea.
Osteoporosis ProphylaxisThe FDA has approved the use ofan estradiol transdermal system(Menostar), from Berlex LaboratoriesInc., to prevent osteoporosis in postmenopausalwomen. The hormoneis impregnated in a dime-sized, once a-week patch that delivers 14 μg/d ofestradiol: this dosage is half that ofother currently available transdermalestrogen patches. No supplementaryprogestin therapy is generally needed.This product can be prescribed for women who are without a uterus.The most common side effects areirritation at the patch site, joint pain,and leukorrhea.
